INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Mar 28, 2006 |
Director
Trans History: 742
|
Director | Form 4 | Bona fide gift | 10,065 | -- | 390,485 |
| Feb 14, 2012 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 234,616 | $13.00 | 390,679 |
| Sep 10, 2014 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Other acquisition or disposition | -- | -- | 390,852 |
| Aug 26, 2014 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 151,537 | $351.62 | 390,852 |
| Feb 14, 2012 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 1,801 | $111.01 | 392,585 |
| Dec 13, 2017 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 14,230 | $385.08 | 393,179 |
| Mar 14, 2022 |
Director
Trans History: 742
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 75,000 | $179.13 | 393,669 |
| Feb 14, 2012 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 15,384 | $13.00 | 394,386 |
| Dec 16, 2014 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 240,000 | -- | 398,079 |
| May 21, 2020 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Open market or private sale of non-derivative or derivative security | 8,359 | $562.48 | 399,038 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.